Literature DB >> 17898315

Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas.

Santiago Montes-Moreno1, Giovanna Roncador, Lorena Maestre, Nerea Martínez, Lydia Sanchez-Verde, Francisca I Camacho, Jimena Cannata, Jorge L Martinez-Torrecuadrada, Yulei Shen, Wing C Chan, Miguel A Piris.   

Abstract

GCET1 (germinal center B cell-expressed transcript-1) gene codes for a serpin expressed in germinal center (GC) B cells. Following the observation that follicular lymphoma cases exhibit an increased level of Gcet1 expression, compared with follicular hyperplasia, we have characterized Gcet1 protein expression in human tissues, cell lines, and a large series of lymphomas. To this end, we have performed immunohistochemical and Western blot analyses using a newly generated monoclonal antibody that is reactive in paraffin-embedded tissues. Our results demonstrate that Gcet1 is expressed exclusively by neoplasms hypothetically to be arrested at the GC stage of differentiation, including follicular lymphoma, nodular lymphocyte predominant Hodgkin lymphoma, and a subset of diffuse large B-cell lymphoma, T-cell/histiocyte rich B-cell lymphoma, and Burkitt lymphoma. Within these tumors, Gcet-1 protein expression is restricted to a subset of GC B cells, establishing the existence of a distinct heterogeneity among normal and neoplastic GC B cells. None of the other B-cell lymphomas, that is, chronic lymphocytic leukemia, splenic marginal zone lymphoma, and mantle cell lymphoma, was Gcet1(+), which underlines the potential utility of Gcet1 expression in lymphoma diagnosis. The results of RNA and protein expression should prompt further investigation into the role of Gcet1 in regulating B-cell survival.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17898315     DOI: 10.1182/blood-2007-06-094151

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

Review 1.  The heterogeneity of follicular lymphomas: from early development to transformation.

Authors:  Luc Xerri; Stephan Dirnhofer; Leticia Quintanilla-Martinez; Birgitta Sander; John K C Chan; Elias Campo; Steven H Swerdlow; German Ott
Journal:  Virchows Arch       Date:  2015-10-19       Impact factor: 4.064

2.  Immunohistochemical algorithm alone is not enough for predicting the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP.

Authors:  Ting-Xun Lu; Qi-Xing Gong; Li Wang; Lei Fan; Xiao-Yan Zhang; Yao-Yu Chen; Zhen Wang; Wei Xu; Zhi-Hong Zhang; Jian-Yong Li
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

3.  Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.

Authors:  C Visco; Y Li; Z Y Xu-Monette; R N Miranda; T M Green; Y Li; A Tzankov; W Wen; W-m Liu; B S Kahl; E S G d'Amore; S Montes-Moreno; K Dybkær; A Chiu; W Tam; A Orazi; Y Zu; G Bhagat; J N Winter; H-Y Wang; S O'Neill; C H Dunphy; E D Hsi; X F Zhao; R S Go; W W L Choi; F Zhou; M Czader; J Tong; X Zhao; J H van Krieken; Q Huang; W Ai; J Etzell; M Ponzoni; A J M Ferreri; M A Piris; M B Møller; C E Bueso-Ramos; L J Medeiros; L Wu; K H Young
Journal:  Leukemia       Date:  2012-03-22       Impact factor: 11.528

4.  Deregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma.

Authors:  Daniel Martín-Pérez; Esther Sánchez; Lorena Maestre; Javier Suela; Pierfrancesco Vargiu; Lorena Di Lisio; Nerea Martínez; Javier Alves; Miguel A Piris; Margarita Sánchez-Beato
Journal:  Am J Pathol       Date:  2010-06-17       Impact factor: 4.307

5.  The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas.

Authors:  Scott J Rodig; Jeffery L Kutok; Jennifer C Paterson; Hiroaki Nitta; Wenjun Zhang; Bjoern Chapuy; Lynette K Tumwine; Santiago Montes-Moreno; Claudio Agostinelli; Nathalie A Johnson; Susana Ben-Neriah; Pedro Farinha; Margaret A Shipp; Miguel A Piris; Thomas M Grogan; Stefano A Pileri; Randy D Gascoyne; Teresa Marafioti
Journal:  Haematologica       Date:  2010-09-07       Impact factor: 9.941

6.  New developments in the pathology of malignant lymphoma: a review of the literature published from January to April 2008.

Authors:  J Han J M van Krieken
Journal:  J Hematop       Date:  2008-07       Impact factor: 0.196

7.  Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France.

Authors:  Leticia Quintanilla-Martinez; Daphne de Jong; Antoine de Mascarel; Eric D Hsi; Philip Kluin; Yaso Natkunam; Marie Parrens; Stefano Pileri; German Ott
Journal:  J Hematop       Date:  2009-12-22       Impact factor: 0.196

8.  Hodgkin's Lymphomas: A Tumor Recognized by Its Microenvironment.

Authors:  S Montes-Moreno
Journal:  Adv Hematol       Date:  2010-10-24

9.  A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.

Authors:  William W L Choi; Dennis D Weisenburger; Timothy C Greiner; Miguel A Piris; Alison H Banham; Jan Delabie; Rita M Braziel; Huimin Geng; Javeed Iqbal; Georg Lenz; Julie M Vose; Christine P Hans; Kai Fu; Lynette M Smith; Min Li; Zhongfeng Liu; Randy D Gascoyne; Andreas Rosenwald; German Ott; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; David L Jaye; Louis M Staudt; Wing C Chan
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

10.  Plasmablastic lymphoma of the retroperitoneum in an HIV- and HCV-positive patient: hard to diagnose and harder to treat.

Authors:  Bhagirathbhai Dholaria; Daisy Alapat; Tarun Pandey; Abhishek Agarwal
Journal:  Med Oncol       Date:  2012-05-06       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.